<p>RNS 编号：7324G Incanthera PLC2025 年 11 月 7 日</p>
<p>2025 年 11 月 7 日</p>
<p>Incanthera plc</p>
<p>（&#34;Incanthera&#34;或&#34;公司&#34;）</p>
<p>2025 年股东大会结果</p>
<p>Incanthera plc（AQSE:INC），一家专注于皮肤病学和肿瘤学创新技术的公司，宣布在 2025 年 11 月 7 日举行的股东大会上，所有决议均已通过。</p>
<p>每项决议的投票详情如下。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>决议</td>
<td>支持</td>
<td>%</td>
<td>反对</td>
<td>%</td>
<td>总计</td>
<td>投票的 ISC 百分比</td>
<td>被弃权 *</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. 接收截至 2025 年 3 月 31 日的公司年度报告和财务报表，以及最新的董事报告和审计师报告</td>
<td>35,632,832</td>
<td>73.17%</td>
<td>13,065,834</td>
<td>26.83%</td>
<td>48,698,666</td>
<td>43%</td>
<td>138,602</td>
<td></td>
</tr>
<tr>
<td>2. 重新选举 Caroline Murray，依据公司章程第 23.4.2 条退休，并且符合条件，愿意再次被选为董事。</td>
<td>48,654,900</td>
<td>99.64%</td>
<td>177,378</td>
<td>0.36%</td>
<td>48,832,278</td>
<td>43%</td>
<td>4,990</td>
<td></td>
</tr>
<tr>
<td>3. 重新选举 Crowe UK LLP 为公司的审计师，直到下次年度股东大会，并授权董事决定其报酬。</td>
<td>48,813,676</td>
<td>100.00%</td>
<td>0</td>
<td>0.00%</td>
<td>48,813,676</td>
<td>43%</td>
<td>23,592</td>
<td></td>
</tr>
<tr>
<td>4. 授权董事分配股份。</td>
<td>48,641,019</td>
<td>99.88%</td>
<td>57,647</td>
<td>0.12%</td>
<td>48,698,666</td>
<td>43%</td>
<td>138,602</td>
<td></td>
</tr>
<tr>
<td>5. 取消法定优先认购权。**</td>
<td>48,541,019</td>
<td>99.68%</td>
<td>157,647</td>
<td>0.32%</td>
<td>48,698,666</td>
<td>43%</td>
<td>138,602</td>
<td></td>
</tr>
</tbody>
</table>
<p>* &#34;支持&#34;和&#34;反对&#34;的投票以投票总数的百分比表示。&#34;支持&#34;的投票包括酌情投票。&#34;被弃权投票&#34;在法律上不算作投票，因此不计入&#34;支持&#34;或&#34;反对&#34;决议的计算中。</p>
<p>** 表示需要 75% 多数通过的特别决议。</p>
<p>尽管所有决议均已通过，但决议 1 的反对票超过 20%。根据 QCA 公司治理准则，董事会确认将继续与相关股东进行咨询和沟通，以进一步了解他们的观点。</p>
<p>公司感谢所有提交代理表格并亲自出席的股东。</p>
<p>本公告包含根据欧盟法规 596/2014 第 7 条的内幕信息（根据 2018 年《欧盟（撤回）法案》成为英国国内法的一部分）。</p>
<p>公司的董事对本公告的内容承担责任。</p>
<p>如需更多信息，请联系：</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Incanthera plc<br/>www.incanthera.com<br/>Tim McCarthy, 主席<br/>tim.mccarthy@incanthera.com<br/>Simon Ward, 首席执行官<br/>simon.ward@incanthera.com<br/>Suzanne Brocks, 公共关系负责人<br/>suzanne.brocks@incanthera.com</td>
<td>+44 (0) 7831 675747<br/>+44 (0) 7747 625506<br/>+44 (0) 7776 234600</td>
</tr>
<tr>
<td>Aquis Exchange 企业顾问：<br/>Cairn Financial Advisers LLP<br/>Jo Turner / Liam Murray / Ed Downes</td>
<td>+44 (0) 20 7213 0880</td>
</tr>
<tr>
<td>经纪人：<br/>Stanford Capital Partners Ltd<br/>Patrick Claridge / Bob Pountney</td>
<td>+44 (0) 20 3650 3650/51</td>
</tr>
</tbody>
</table>
<p>编辑注释</p>
<p>关于 Incanthera plc</p>
<p>Incanthera 是一家总部位于英国的皮肤病学和肿瘤学治疗公司，专注于发现和开发针对性解决方案。公司开发了复杂的配方和靶向技术平台，以解决皮肤病学和肿瘤学中以前无法获得的选择，能够将治疗特定地传递到所需部位，实现有效成分的精准靶向，以达到最佳疗效。</p>
<p>Incanthera 致力于识别和开发创新解决方案，以满足当前临床和商业上相关的未满足需求，结合行业和领先学术界的新技术，以及其内部开发团队，利用其独特的靶向递送平台。</p>
<p>公司的当前重点是 Skin + CELL，Incanthera 独特的奢华护肤品牌，涵盖一系列皮肤病学应用，以满足护肤市场上当前未满足的需求。</p>
<p>有关公司的更多信息，请访问：www.incanthera.com</p>
<p>@incantheraplc</p>
<p>关于 Skin + CELL</p>
<p>Skin + CELL 是 Incanthera 的奢华护肤品牌，于 2025 年 8 月推出。我们的突破性配方和递送专业知识将科学证明的配方带入化妆品。Skin + CELL 的互补产品系列基于先进的、临床设计的配方浓缩物，结合前沿的递送增强技术与精选的高端化妆品成分，提供有效的产品，使用时具有丝滑的润肤感，使肌肤看起来光彩照人、充满活力并得到保护。</p>
<p>Incanthera 的新型生物活性护肤技术由我们内部专家开发，他们曾为一些全球领先的护肤和制药公司配制外用产品。这些配方强化了本来被耗竭的生理通路，以改善皮肤的表现、自我修复能力，并解决皮肤健康中以前未满足的美容问题。</p>
<p>Skin + CELL 的奢华护肤当前系列涵盖面部、身体、手部、面部精华和眼霜，未来还将包括生物活性防晒浓度和维生素的进一步衍生物。</p>
<p>www.skinandcell.com</p>
<p>此信息由 RNS 提供，伦敦证券交易所的新闻服务。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
<p>RNS 可能会使用您的 IP 地址来确认您是否遵守条款和条件，分析您如何与本次沟通中包含的信息互动，并将此分析以匿名方式与他人分享，作为我们商业服务的一部分。有关 RNS 和伦敦证券交易所如何使用您提供的个人数据的更多信息，请参阅我们的隐私政策。END NEXUPGUGGUPAGCM</p>

<p>Incanthera PLC 宣布了其于 2025 年 11 月 7 日举行的年度股东大会（AGM）结果，所有决议均已通过。值得注意的是，决议 1 收到了超过 20% 的反对票，这促使董事会与股东进行进一步沟通以获取更多见解。该公司专注于创新的皮肤病学和肿瘤学技术，并推出了其奢侈护肤品牌 Skin + CELL，旨在满足护肤市场中的未满足需求。该公告包含根据欧盟法规的内部信息</p>

<p>RNS Number : 7324G Incanthera PLC 07 November 2025</p>
<div class="lb-trans"><p>RNS 编号：7324G Incanthera PLC2025 年 11 月 7 日</p>
</div><p>7 November 2025</p>
<div class="lb-trans"><p>2025 年 11 月 7 日</p>
</div><p>Incanthera plc</p>
<div class="lb-trans"><p>Incanthera plc</p>
</div><p>(&#34;Incanthera&#34; the &#34;Company&#34;)</p>
<div class="lb-trans"><p>（&#34;Incanthera&#34;或&#34;公司&#34;）</p>
</div><p>Result of AGM 2025</p>
<div class="lb-trans"><p>2025 年股东大会结果</p>
</div><p>Incanthera plc (AQSE:INC), the company focused on innovative technologies in dermatology and oncology announces that at its AGM held on 7 November 2025 all resolutions were duly passed.</p>
<div class="lb-trans"><p>Incanthera plc（AQSE:INC），一家专注于皮肤病学和肿瘤学创新技术的公司，宣布在 2025 年 11 月 7 日举行的股东大会上，所有决议均已通过。</p>
</div><p>Details of the votes cast for each Resolution are as follows.</p>
<div class="lb-trans"><p>每项决议的投票详情如下。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Resolution</td>
<td>For</td>
<td>%</td>
<td>Against</td>
<td>%</td>
<td>Total</td>
<td>% of ISC voted</td>
<td>Withheld*</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. To receive the company's annual reports and accounts for the financial year ended 31 March 2025 together with the latest Directors' Report and the Auditors' Report of the Company</td>
<td>35,632,832</td>
<td>73.17%</td>
<td>13,065,834</td>
<td>26.83%</td>
<td>48,698,666</td>
<td>43%</td>
<td>138,602</td>
<td></td>
</tr>
<tr>
<td>2. To re-elect Caroline Murray, who retires under article 23.4.2 of the Company's articles of association and who, being eligible, offers herself for re-election as a Director.</td>
<td>48,654,900</td>
<td>99.64%</td>
<td>177,378</td>
<td>0.36%</td>
<td>48,832,278</td>
<td>43%</td>
<td>4,990</td>
<td></td>
</tr>
<tr>
<td>3. To re-elect Crowe UK LLP as auditors of the Company until the next annual general meeting of the Company and to authorise the directors to determine their remuneration.</td>
<td>48,813,676</td>
<td>100.00%</td>
<td>0</td>
<td>0.00%</td>
<td>48,813,676</td>
<td>43%</td>
<td>23,592</td>
<td></td>
</tr>
<tr>
<td>4. To authorise the directors to allot shares.</td>
<td>48,641,019</td>
<td>99.88%</td>
<td>57,647</td>
<td>0.12%</td>
<td>48,698,666</td>
<td>43%</td>
<td>138,602</td>
<td></td>
</tr>
<tr>
<td>5. To disapply the statutory pre-emption provisions.**</td>
<td>48,541,019</td>
<td>99.68%</td>
<td>157,647</td>
<td>0.32%</td>
<td>48,698,666</td>
<td>43%</td>
<td>138,602</td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>决议</td>
<td>支持</td>
<td>%</td>
<td>反对</td>
<td>%</td>
<td>总计</td>
<td>投票的 ISC 百分比</td>
<td>被弃权 *</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. 接收截至 2025 年 3 月 31 日的公司年度报告和财务报表，以及最新的董事报告和审计师报告</td>
<td>35,632,832</td>
<td>73.17%</td>
<td>13,065,834</td>
<td>26.83%</td>
<td>48,698,666</td>
<td>43%</td>
<td>138,602</td>
<td></td>
</tr>
<tr>
<td>2. 重新选举 Caroline Murray，依据公司章程第 23.4.2 条退休，并且符合条件，愿意再次被选为董事。</td>
<td>48,654,900</td>
<td>99.64%</td>
<td>177,378</td>
<td>0.36%</td>
<td>48,832,278</td>
<td>43%</td>
<td>4,990</td>
<td></td>
</tr>
<tr>
<td>3. 重新选举 Crowe UK LLP 为公司的审计师，直到下次年度股东大会，并授权董事决定其报酬。</td>
<td>48,813,676</td>
<td>100.00%</td>
<td>0</td>
<td>0.00%</td>
<td>48,813,676</td>
<td>43%</td>
<td>23,592</td>
<td></td>
</tr>
<tr>
<td>4. 授权董事分配股份。</td>
<td>48,641,019</td>
<td>99.88%</td>
<td>57,647</td>
<td>0.12%</td>
<td>48,698,666</td>
<td>43%</td>
<td>138,602</td>
<td></td>
</tr>
<tr>
<td>5. 取消法定优先认购权。**</td>
<td>48,541,019</td>
<td>99.68%</td>
<td>157,647</td>
<td>0.32%</td>
<td>48,698,666</td>
<td>43%</td>
<td>138,602</td>
<td></td>
</tr>
</tbody>
</table>
</div><p>* Votes &#34;For&#34; and &#34;Against&#34; are expressed as a percentage of votes cast. Votes &#34;For&#34; include discretionary votes. A &#34;Vote withheld&#34; is not a vote in law and is therefore not counted in the calculation of the votes &#34;For&#34; or &#34;Against&#34; a resolution.</p>
<div class="lb-trans"><p>* &#34;支持&#34;和&#34;反对&#34;的投票以投票总数的百分比表示。&#34;支持&#34;的投票包括酌情投票。&#34;被弃权投票&#34;在法律上不算作投票，因此不计入&#34;支持&#34;或&#34;反对&#34;决议的计算中。</p>
</div><p>** Indicates special resolutions requiring a 75% majority.</p>
<div class="lb-trans"><p>** 表示需要 75% 多数通过的特别决议。</p>
</div><p>While all resolutions were duly passed, Resolution 1 received over 20% of votes against it. In accordance with the QCA Corporate Governance Code, the Board confirms that it will continue to consult and engage with the relevant shareholders with respect to Resolution 1 to further understand their views.</p>
<div class="lb-trans"><p>尽管所有决议均已通过，但决议 1 的反对票超过 20%。根据 QCA 公司治理准则，董事会确认将继续与相关股东进行咨询和沟通，以进一步了解他们的观点。</p>
</div><p>The Company would like to thank all Shareholders who returned their Proxy form and attended in person.</p>
<div class="lb-trans"><p>公司感谢所有提交代理表格并亲自出席的股东。</p>
</div><p>This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).</p>
<div class="lb-trans"><p>本公告包含根据欧盟法规 596/2014 第 7 条的内幕信息（根据 2018 年《欧盟（撤回）法案》成为英国国内法的一部分）。</p>
</div><p>The Directors of the Company accept responsibility for the content of this announcement.</p>
<div class="lb-trans"><p>公司的董事对本公告的内容承担责任。</p>
</div><p>For further information please contact:</p>
<div class="lb-trans"><p>如需更多信息，请联系：</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Incanthera plc<br/>www.incanthera.com<br/>Tim McCarthy, Chairman<br/>tim.mccarthy@incanthera.com<br/>Simon Ward, Chief Executive Officer<br/>simon.ward@incanthera.com<br/>Suzanne Brocks, Head of Communications<br/>suzanne.brocks@incanthera.com</td>
<td>+44 (0) 7831 675747<br/>+44 (0) 7747 625506<br/>+44 (0) 7776 234600</td>
</tr>
<tr>
<td>Aquis Exchange Corporate Adviser: <br/>Cairn Financial Advisers LLP<br/>Jo Turner / Liam Murray / Ed Downes</td>
<td>+44 (0) 20 7213 0880</td>
</tr>
<tr>
<td>Broker: <br/>Stanford Capital Partners Ltd<br/>Patrick Claridge / Bob Pountney</td>
<td>+44 (0) 20 3650 3650/51</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Incanthera plc<br/>www.incanthera.com<br/>Tim McCarthy, 主席<br/>tim.mccarthy@incanthera.com<br/>Simon Ward, 首席执行官<br/>simon.ward@incanthera.com<br/>Suzanne Brocks, 公共关系负责人<br/>suzanne.brocks@incanthera.com</td>
<td>+44 (0) 7831 675747<br/>+44 (0) 7747 625506<br/>+44 (0) 7776 234600</td>
</tr>
<tr>
<td>Aquis Exchange 企业顾问：<br/>Cairn Financial Advisers LLP<br/>Jo Turner / Liam Murray / Ed Downes</td>
<td>+44 (0) 20 7213 0880</td>
</tr>
<tr>
<td>经纪人：<br/>Stanford Capital Partners Ltd<br/>Patrick Claridge / Bob Pountney</td>
<td>+44 (0) 20 3650 3650/51</td>
</tr>
</tbody>
</table>
</div><p>Notes to Editors</p>
<div class="lb-trans"><p>编辑注释</p>
</div><p>About Incanthera plc</p>
<div class="lb-trans"><p>关于 Incanthera plc</p>
</div><p>Incanthera is a UK-based, dermatology and oncology therapeutics company focusing on discovery and development of targeted solutions. The Company has developed sophisticated formulation and targeting technology platforms to address previously unavailable options across dermatology and oncology, delivering treatments specifically to a required site, enabling effective ingredients with precision targeting for optimal efficacy.</p>
<div class="lb-trans"><p>Incanthera 是一家总部位于英国的皮肤病学和肿瘤学治疗公司，专注于发现和开发针对性解决方案。公司开发了复杂的配方和靶向技术平台，以解决皮肤病学和肿瘤学中以前无法获得的选择，能够将治疗特定地传递到所需部位，实现有效成分的精准靶向，以达到最佳疗效。</p>
</div><p>Identifying and developing innovative solutions to current clinical, commercially relevant unmet needs, Incanthera combines new technology from industry and leading academics, as well as its in-house development team, with its unique targeting delivery platform.</p>
<div class="lb-trans"><p>Incanthera 致力于识别和开发创新解决方案，以满足当前临床和商业上相关的未满足需求，结合行业和领先学术界的新技术，以及其内部开发团队，利用其独特的靶向递送平台。</p>
</div><p>The Company's current focus is Skin + CELL, Incanthera's unique luxury skincare brand in a range of dermatological applications to meet currently unmet needs in the skincare market.</p>
<div class="lb-trans"><p>公司的当前重点是 Skin + CELL，Incanthera 独特的奢华护肤品牌，涵盖一系列皮肤病学应用，以满足护肤市场上当前未满足的需求。</p>
</div><p>For more information on the Company please visit: www.incanthera.com</p>
<div class="lb-trans"><p>有关公司的更多信息，请访问：www.incanthera.com</p>
</div><p>@incantheraplc</p>
<div class="lb-trans"><p>@incantheraplc</p>
</div><p>About Skin + CELL</p>
<div class="lb-trans"><p>关于 Skin + CELL</p>
</div><p>Skin + CELL is Incanthera's luxury skincare brand utilising, launched in August 2025. Our ground-breaking formulation and delivery expertise brings scientifically proven formulations to cosmetics. Skin + CELL's complementary range of products are based on advanced, clinically designed, formulation concentrates which combine leading edge delivery enhancement technology with selected prestige cosmetic ingredients to give an effective product which gives a silky emollience in use and leaves the skin visibly radiant, energised and protected.</p>
<div class="lb-trans"><p>Skin + CELL 是 Incanthera 的奢华护肤品牌，于 2025 年 8 月推出。我们的突破性配方和递送专业知识将科学证明的配方带入化妆品。Skin + CELL 的互补产品系列基于先进的、临床设计的配方浓缩物，结合前沿的递送增强技术与精选的高端化妆品成分，提供有效的产品，使用时具有丝滑的润肤感，使肌肤看起来光彩照人、充满活力并得到保护。</p>
</div><p>Incanthera's new bioactive skincare technology has been developed by our in-house experts who have previously formulated topical products for some of the world's leading skincare and pharmaceutical companies. The formulations fortify otherwise depleted physiological pathways to improve the skin's performance, ability to self-repair and to address previously unmet cosmetic conditions in skin health.</p>
<div class="lb-trans"><p>Incanthera 的新型生物活性护肤技术由我们内部专家开发，他们曾为一些全球领先的护肤和制药公司配制外用产品。这些配方强化了本来被耗竭的生理通路，以改善皮肤的表现、自我修复能力，并解决皮肤健康中以前未满足的美容问题。</p>
</div><p>Skin + CELL's luxury skincare current range extends across face, body, hand, face serum and eye cream, and will also include bioactive SPF concentrations and further derivatives of vitamins in the future.</p>
<div class="lb-trans"><p>Skin + CELL 的奢华护肤当前系列涵盖面部、身体、手部、面部精华和眼霜，未来还将包括生物活性防晒浓度和维生素的进一步衍生物。</p>
</div><p>www.skinandcell.com</p>
<div class="lb-trans"><p>www.skinandcell.com</p>
</div><p>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</p>
<div class="lb-trans"><p>此信息由 RNS 提供，伦敦证券交易所的新闻服务。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
</div><p>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END NEXUPGUGGUPAGCM</p>
<div class="lb-trans"><p>RNS 可能会使用您的 IP 地址来确认您是否遵守条款和条件，分析您如何与本次沟通中包含的信息互动，并将此分析以匿名方式与他人分享，作为我们商业服务的一部分。有关 RNS 和伦敦证券交易所如何使用您提供的个人数据的更多信息，请参阅我们的隐私政策。END NEXUPGUGGUPAGCM</p>
</div>

Incanthera PLC - 股东大会结果